{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T15:44:17Z","timestamp":1784735057096,"version":"3.55.0"},"reference-count":134,"publisher":"Spandidos Publications","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Ther Med"],"DOI":"10.3892\/etm.2021.10898","type":"journal-article","created":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T05:48:43Z","timestamp":1634708923000},"source":"Crossref","is-referenced-by-count":4,"title":["Mechanism and prevention strategy of a bidirectional relationship between heart failure and cancer (Review)"],"prefix":"10.3892","volume":"22","author":[{"given":"He","family":"Cai","sequence":"first","affiliation":[{"name":"Cardiovascular Center, The First Hospital of Jilin University, Jilin University, Changchun, Jilin 130021, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbo","family":"Men","sequence":"additional","affiliation":[{"name":"Cardiovascular Center, The First Hospital of Jilin University, Jilin University, Changchun, Jilin 130021, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengyu","family":"Cao","sequence":"additional","affiliation":[{"name":"Cardiovascular Center, The First Hospital of Jilin University, Jilin University, Changchun, Jilin 130021, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zheng","sequence":"additional","affiliation":[{"name":"Cardiovascular Center, The First Hospital of Jilin University, Jilin University, Changchun, Jilin 130021, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2021,10,20]]},"reference":[{"key":"key20211117123226_b1-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1002\/ejhf.567","article-title":"Heart failure epidemiology 2000-2013: Insights from the German federal health monitoring system","volume":"18","author":"Christ","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"key20211117123226_b2-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"290","DOI":"10.3322\/caac.21340","article-title":"Cancer statistics for African Americans, 2016: Progress and opportunities in reducing racial disparities","volume":"66","author":"DeSantis","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"key20211117123226_b3-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1200\/JCO.2015.64.0409","article-title":"Cardiovascular disease among survivors of adult-onset cancer: A community-based retrospective cohort study","volume":"34","author":"Armenian","year":"2016","journal-title":"J Clin Oncol"},{"key":"key20211117123226_b4-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3904\/kjim.2018.428","article-title":"Update on heart failure management and future directions","volume":"34","author":"Choi","year":"2019","journal-title":"Korean J Intern Med"},{"key":"key20211117123226_b5-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1002\/cncr.11407","article-title":"Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials","volume":"97","author":"Swain","year":"2003","journal-title":"Cancer"},{"key":"key20211117123226_b6-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1161\/CIRCULATIONAHA.116.025434","article-title":"Risk of heart failure with preserved ejection fraction in older women after contemporary radiotherapy for breast cancer","volume":"135","author":"Saiki","year":"2017","journal-title":"Circulation"},{"key":"key20211117123226_b7-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"key20211117123226_b8-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1161\/CIRCULATIONAHA.113.006242","article-title":"Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis","volume":"129","author":"Quarta","year":"2014","journal-title":"Circulation"},{"key":"key20211117123226_b9-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1001\/jamainternmed.2015.1180","article-title":"Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk","volume":"175","author":"van Nimwegen","year":"2015","journal-title":"JAMA Intern Med"},{"key":"key20211117123226_b10-ETM-22-6-10898","first-page":"564","article-title":"Cancer therapeutics-related cardiac dysfunction among patients with active breast cancer: A cardio-oncology registry","volume":"22","author":"Laufer-Perl","year":"2020","journal-title":"Isr Med Assoc J"},{"issue":"1139","key":"key20211117123226_b11-ETM-22-6-10898","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07663-x","article-title":"High cumulative doxorubicin dose for advanced soft tissue sarcoma","volume":"20","author":"Tian","year":"2020","journal-title":"BMC Cancer"},{"issue":"e036492","key":"key20211117123226_b12-ETM-22-6-10898","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-036492","article-title":"Are patients with stage III non-small cell lung cancer treated with chemoradiotherapy at risk for cardiac events? Results from a retrospective cohort study","volume":"10","author":"Degens","year":"2020","journal-title":"BMJ Open"},{"key":"key20211117123226_b13-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1056\/NEJMoa0706201","article-title":"Rosuvastatin in older patients with systolic heart failure","volume":"357","author":"Kjekshus","year":"2007","journal-title":"N Engl J Med"},{"key":"key20211117123226_b14-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1016\/j.jacc.2008.08.027","article-title":"Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms","volume":"52","author":"Linde","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"key20211117123226_b15-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1056\/NEJMoa0906431","article-title":"Cardiac-resynchronization therapy for the prevention of heart-failure events","volume":"361","author":"Moss","year":"2009","journal-title":"N Engl J Med"},{"key":"key20211117123226_b16-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1056\/NEJMoa1306687","article-title":"Cardiac-resynchronization therapy in heart failure with a narrow QRS complex","volume":"369","author":"Ruschitzka","year":"2013","journal-title":"N Engl J Med"},{"key":"key20211117123226_b17-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"key20211117123226_b18-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/s0140-6736(94)91895-3","article-title":"Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA)","volume":"344","author":"Doval","year":"1994","journal-title":"Lancet"},{"key":"key20211117123226_b19-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1056\/NEJM199711273372201","article-title":"Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary artery bypass graft (CABG) patch trial investigators","volume":"337","author":"Bigger","year":"1997","journal-title":"N Engl J Med"},{"key":"key20211117123226_b20-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1056\/NEJMoa033088","article-title":"Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy","volume":"350","author":"Kadish","year":"2004","journal-title":"N Engl J Med"},{"key":"key20211117123226_b21-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: The CHARM-alternative trial","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"key":"key20211117123226_b22-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-added trial","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"key":"key20211117123226_b23-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1056\/NEJMoa0708789","article-title":"Rhythm control versus rate control for atrial fibrillation and heart failure","volume":"358","author":"Roy","year":"2008","journal-title":"N Engl J Med"},{"key":"key20211117123226_b24-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/S0140-6736(08)61239-8","article-title":"Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): A randomised, double-blind, placebo-controlled trial","volume":"372","author":"Tavazzi","year":"2008","journal-title":"Lancet"},{"key":"key20211117123226_b25-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1056\/NEJMoa1100356","article-title":"Coronary-artery bypass surgery in patients with left ventricular dysfunction","volume":"364","author":"Velazquez","year":"2011","journal-title":"N Engl J Med"},{"key":"key20211117123226_b26-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1161\/CIRCULATIONAHA.118.033603","article-title":"Linking heart failure to cancer: Background evidence and research perspectives","volume":"138","author":"Bertero","year":"2018","journal-title":"Circulation"},{"key":"key20211117123226_b27-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1161\/CIRCULATIONAHA.117.030816","article-title":"Heart failure stimulates tumor growth by circulating factors","volume":"138","author":"Meijers","year":"2018","journal-title":"Circulation"},{"key":"key20211117123226_b28-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"106","DOI":"10.15420\/cfr.2019.1.2","article-title":"Bidirectional relationship between cancer and heart failure: Old and new issues in cardio-oncology","volume":"5","author":"Bertero","year":"2019","journal-title":"Card Fail Rev"},{"issue":"598384","key":"key20211117123226_b29-ETM-22-6-10898","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2020.598384","article-title":"Development of cancer in patients with heart failure: How systemic inflammation can lay the groundwork","volume":"7","author":"Ausoni","year":"2020","journal-title":"Front Cardiovasc Med"},{"key":"key20211117123226_b30-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/1097-0142(1967)20:3<333::aid-cncr2820200302>3.0.co;2-k","article-title":"Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia","volume":"20","author":"Tan","year":"1967","journal-title":"Cancer"},{"key":"key20211117123226_b31-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s11764-011-0186-6","article-title":"Late cardiotoxicity after low dose of anthracycline therapy for acute lymphoblastic leukemia in childhood","volume":"6","author":"Vandecruys","year":"2012","journal-title":"J Cancer Surviv"},{"key":"key20211117123226_b32-ETM-22-6-10898","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1021\/bi00462a016","article-title":"Structural comparison of anticancer drug-DNA complexes: Adriamycin and daunomycin","volume":"29","author":"Frederick","year":"1990","journal-title":"Biochemistry"},{"key":"key20211117123226_b33-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.tox.2008.10.011","article-title":"Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy","volume":"255","author":"Martin","year":"2009","journal-title":"Toxicology"},{"key":"key20211117123226_b34-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1038\/nm.2919","article-title":"Identification of the molecular basis of doxorubicin-induced cardiotoxicity","volume":"18","author":"Zhang","year":"2012","journal-title":"Nat Med"},{"key":"key20211117123226_b35-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1586\/14779072.6.10.1311","article-title":"Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity","volume":"6","author":"Jones","year":"2008","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"key20211117123226_b36-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1007\/s12012-019-09554-5","article-title":"The role of topoisomerase II\u03b2 in the mechanisms of action of the doxorubicin cardioprotective agent dexrazoxane","volume":"20","author":"Hasinoff","year":"2020","journal-title":"Cardiovasc Toxicol"},{"key":"key20211117123226_b37-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1002\/jat.782","article-title":"Potential protective role of angiotensin-converting enzyme inhibitors captopril and enalapril against adriamycin-induced acute cardiac and hepatic toxicity in rats","volume":"21","author":"Abd El-Aziz","year":"2001","journal-title":"J Appl Toxicol"},{"key":"key20211117123226_b38-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1161\/CIRCULATIONAHA.117.030352","article-title":"Phosphoinositide 3-kinase gamma inhibition protects from anthracycline cardiotoxicity and reduces tumor growth","volume":"138","author":"Li","year":"2018","journal-title":"Circulation"},{"key":"key20211117123226_b39-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1126\/science.1060191","article-title":"Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice","volume":"293","author":"Paris","year":"2001","journal-title":"Science"},{"key":"key20211117123226_b40-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1136\/hrt.69.6.496","article-title":"Severe coronary artery disease after radiation therapy of the chest and mediastinum: Clinical presentation and treatment","volume":"69","author":"Orzan","year":"1993","journal-title":"Br Heart J"},{"issue":"385","key":"key20211117123226_b41-ETM-22-6-10898","doi-asserted-by":"publisher","DOI":"10.1007\/s00395-013-0385-6","article-title":"Ionizing radiation regulates cardiac Ca handling via increased ROS and activated CaMKII","volume":"108","author":"Sag","year":"2013","journal-title":"Basic Res Cardiol"},{"key":"key20211117123226_b42-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1161\/CIRCRESAHA.109.205906","article-title":"The vulnerability of the heart as a pluricellular paracrine organ: Lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy","volume":"106","author":"De Keulenaer","year":"2010","journal-title":"Circ Res"},{"key":"key20211117123226_b43-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"3859","DOI":"10.1200\/JCO.2006.09.1611","article-title":"Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial","volume":"25","author":"Suter","year":"2007","journal-title":"J Clin Oncol"},{"key":"key20211117123226_b44-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/nrc1093","article-title":"Tumorigenesis and the angiogenic switch","volume":"3","author":"Bergers","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"key20211117123226_b45-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.7754\/Clin.Lab.2016.151229","article-title":"High concentrations of the angiogenic peptide VEGF-A in seminal fluid and its association to prostasomes","volume":"62","author":"Carlsson","year":"2016","journal-title":"Clin Lab"},{"key":"key20211117123226_b46-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1002\/ajh.21277","article-title":"Hemostatic complications of angiogenesis inhibitors in cancer patients","volume":"83","author":"Elice","year":"2008","journal-title":"Am J Hematol"},{"key":"key20211117123226_b47-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1053\/j.seminoncol.2003.08.013","article-title":"A phase I\/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer","volume":"30 (5 Suppl 16)","author":"Cobleigh","year":"2003","journal-title":"Semin Oncol"},{"key":"key20211117123226_b48-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1161\/HYPERTENSIONAHA.109.149690","article-title":"Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels","volume":"56","author":"Kappers","year":"2010","journal-title":"Hypertension"},{"key":"key20211117123226_b49-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/j.jacc.2015.07.025","article-title":"Vascular and metabolic implications of novel targeted cancer therapies: Focus on kinase inhibitors","volume":"66","author":"Li","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"key20211117123226_b50-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1093\/cvr\/cvz021","article-title":"Microparticles from vascular endothelial growth factor pathway inhibitor-treated cancer patients mediate endothelial cell injury","volume":"115","author":"Neves","year":"2019","journal-title":"Cardiovasc Res"},{"key":"key20211117123226_b51-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.2459\/JCM.0000000000000377","article-title":"Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors","volume":"17 (Suppl 1)","author":"Maurea","year":"2016","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"key20211117123226_b52-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"5204","DOI":"10.1200\/JCO.2007.15.6331","article-title":"Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma","volume":"26","author":"Schmidinger","year":"2008","journal-title":"J Clin Oncol"},{"key":"key20211117123226_b53-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"issue":"e174519","key":"key20211117123226_b54-ETM-22-6-10898","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.4519","article-title":"Carfilzomib-associated cardiovascular adverse events: A systematic review and meta-analysis","volume":"4","author":"Waxman","year":"2018","journal-title":"JAMA Oncol"},{"key":"key20211117123226_b55-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1093\/eurjhf\/hft034","article-title":"Primary proteasome inhibition results in cardiac dysfunction","volume":"15","author":"Herrmann","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"key20211117123226_b56-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1152\/physrev.00036.2011","article-title":"hERG K(+) channels: Structure, function, and clinical significance","volume":"92","author":"Vandenberg","year":"2012","journal-title":"Physiol Rev"},{"key":"key20211117123226_b57-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1124\/mol.113.091439","article-title":"Long-term channel block is required to inhibit cellular transformation by human ether-\u00e0-go-go-related gene (hERG1) potassium channels","volume":"86","author":"Pier","year":"2014","journal-title":"Mol Pharmacol"},{"key":"key20211117123226_b58-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.phrs.2008.01.009","article-title":"The hERG K+ channel: Target and antitarget strategies in drug development","volume":"57","author":"Raschi","year":"2008","journal-title":"Pharmacol Res"},{"key":"key20211117123226_b59-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1517\/17425255.2.1.81","article-title":"Molecular mechanisms for drug interactions with hERG that cause long QT syndrome","volume":"2","author":"Stansfeld","year":"2006","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"188355","key":"key20211117123226_b60-ETM-22-6-10898","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2020.188355","article-title":"HERG channel and cancer: A mechanistic review of carcinogenic processes and therapeutic potential","volume":"1873","author":"He","year":"2020","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"key20211117123226_b61-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/j.jacc.2016.06.053","article-title":"AL (Light-Chain) cardiac amyloidosis: A review of diagnosis and therapy","volume":"68","author":"Falk","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"key20211117123226_b62-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1016\/j.jacc.2015.09.075","article-title":"Diagnosis, prognosis, and therapy of transthyretin amyloidosis","volume":"66","author":"Gertz","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"key20211117123226_b63-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1161\/01.RES.0000126569.75419.74","article-title":"Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress","volume":"94","author":"Brenner","year":"2004","journal-title":"Circ Res"},{"key":"key20211117123226_b64-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1006\/jmcc.2002.1526","article-title":"Role of oxidative stress in myocardial hypertrophy and failure","volume":"34","author":"Sawyer","year":"2002","journal-title":"J Mol Cell Cardiol"},{"key":"key20211117123226_b65-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1161\/01.cir.77.2.264","article-title":"Carcinoid heart disease: Relationship of circulating vasoactive substances to ultrasound-detectable cardiac abnormalities","volume":"77","author":"Lundin","year":"1988","journal-title":"Circulation"},{"key":"key20211117123226_b66-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1002\/(sici)1097-0142(19970215)79:4<813::aid-cncr19>3.0.co;2-2","article-title":"An analysis of 8305 cases of carcinoid tumors","volume":"79","author":"Modlin","year":"1997","journal-title":"Cancer"},{"key":"key20211117123226_b67-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1136\/heartjnl-2017-311261","article-title":"Carcinoid heart disease","volume":"103","author":"Hassan","year":"2017","journal-title":"Heart"},{"key":"key20211117123226_b68-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"3122","DOI":"10.1161\/01.CIR.0000133187.74800.B9","article-title":"Cardiovascular complications of cancer therapy: Diagnosis, pathogenesis, and management","volume":"109","author":"Yeh","year":"2004","journal-title":"Circulation"},{"key":"key20211117123226_b69-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"3672","DOI":"10.1172\/JCI67266","article-title":"Isocitrate dehydrogenase mutations in leukemia","volume":"123","author":"McKenney","year":"2013","journal-title":"J Clin Invest"},{"key":"key20211117123226_b70-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"10436","DOI":"10.1073\/pnas.1601650113","article-title":"Oncometabolite d-2-hydroxyglutarate impairs \u03b1-ketoglutarate dehydrogenase and contractile function in rodent heart","volume":"113","author":"Karlstaedt","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20211117123226_b71-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s10654-017-0231-5","article-title":"Myocardial infarction and future risk of cancer in the general population-the Troms\u00f8 study","volume":"32","author":"Rinde","year":"2017","journal-title":"Eur J Epidemiol"},{"key":"key20211117123226_b72-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"546","DOI":"10.2459\/JCM.0000000000000701","article-title":"Neoplastic disease after acute coronary syndrome: Incidence, duration, and features: The ABC-4* study on heart disease","volume":"19","author":"Berton","year":"2018","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"key20211117123226_b73-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1002\/ejhf.1539","article-title":"Cancer and heart disease: Associations and relations","volume":"21","author":"de Boer","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"key20211117123226_b74-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1016\/j.jacc.2006.06.063","article-title":"Cardiovascular proteomics: Tools to develop novel biomarkers and potential applications","volume":"48","author":"Arab","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"key20211117123226_b75-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/HCO.0b013e3282f43039","article-title":"Biomarkers in heart failure management","volume":"23","author":"Isaac","year":"2008","journal-title":"Curr Opin Cardiol"},{"issue":"e003101","key":"key20211117123226_b76-ETM-22-6-10898","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.003101","article-title":"Cardiac-secreted factors as peripheral metabolic regulators and potential disease biomarkers","volume":"5","author":"Dewey","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"key20211117123226_b77-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1136\/heartjnl-2015-307848","article-title":"Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality","volume":"101","author":"Pavo","year":"2015","journal-title":"Heart"},{"issue":"e0126741","key":"key20211117123226_b78-ETM-22-6-10898","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0126741","article-title":"N-terminal pro-brain natriuretic peptide is associated with a future diagnosis of cancer in patients with coronary artery disease","volume":"10","author":"Tu\u00f1\u00f3n","year":"2015","journal-title":"PLoS One"},{"key":"key20211117123226_b79-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/ejhf.273","article-title":"State of the Art: Newer biomarkers in heart failure","volume":"17","author":"de Boer","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"key20211117123226_b80-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/nrcardio.2016.163","article-title":"Neurohormonal activation in heart failure with reduced ejection fraction","volume":"14","author":"Hartupee","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"key20211117123226_b81-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/nrc2945","article-title":"The renin-angiotensin system and cancer: Old dog, new tricks","volume":"10","author":"George","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"key20211117123226_b82-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/sj.bjc.6602961","article-title":"Angiotensin II type 1 receptor expression in ovarian cancer and its correlation with tumour angiogenesis and patient survival","volume":"94","author":"Ino","year":"2006","journal-title":"Br J Cancer"},{"issue":"1457","key":"key20211117123226_b83-ETM-22-6-10898","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12061457","article-title":"Renin-angiotensin system in lung tumor and microenvironment interactions","volume":"12","author":"Catarata","year":"2020","journal-title":"Cancers (Basel)"},{"key":"key20211117123226_b84-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S0140-6736(98)03228-0","article-title":"Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?","volume":"352","author":"Lever","year":"1998","journal-title":"Lancet"},{"key":"key20211117123226_b85-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1177\/1753944708091777","article-title":"The therapeutic role of RAS blockade in chronic heart failure","volume":"2","author":"Werner","year":"2008","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"key20211117123226_b86-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1016\/j.freeradbiomed.2010.09.006","article-title":"Oxidative stress, inflammation, and cancer: How are they linked?","volume":"49","author":"Reuter","year":"2010","journal-title":"Free Radic Biol Med"},{"key":"key20211117123226_b87-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1161\/01.HYP.0000254415.31362.a7","article-title":"Role of oxidative stress in cardiac hypertrophy and remodeling","volume":"49","author":"Takimoto","year":"2007","journal-title":"Hypertension"},{"key":"key20211117123226_b88-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.cmet.2014.12.013","article-title":"Essential role for oxidative phosphorylation in cancer progression","volume":"21","author":"Maiuri","year":"2015","journal-title":"Cell Metab"},{"key":"key20211117123226_b89-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1139\/y03-097","article-title":"Dietary restriction and fibre supplementation: Oxidative stress and metabolic shifting for cardiac health","volume":"81","author":"Diniz","year":"2003","journal-title":"Can J Physiol Pharmacol"},{"key":"key20211117123226_b90-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1093\/annonc\/mdr589","article-title":"Dietary fiber and breast cancer risk: A systematic review and meta-analysis of prospective studies","volume":"23","author":"Aune","year":"2012","journal-title":"Ann Oncol"},{"key":"key20211117123226_b91-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1152\/physrev.00015.2009","article-title":"Myocardial fatty acid metabolism in health and disease","volume":"90","author":"Lopaschuk","year":"2010","journal-title":"Physiol Rev"},{"key":"key20211117123226_b92-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ccr.2006.10.020","article-title":"A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth","volume":"11","author":"Bonnet","year":"2007","journal-title":"Cancer Cell"},{"key":"key20211117123226_b93-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1161\/CIRCRESAHA.116.302317","article-title":"Innate immunity and the failing heart: The cytokine hypothesis revisited","volume":"116","author":"Mann","year":"2015","journal-title":"Circ Res"},{"key":"key20211117123226_b94-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0140-6736(17)32814-3","article-title":"Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: A secondary analysis from the CANTOS randomised controlled trial","volume":"391","author":"Ridker","year":"2018","journal-title":"Lancet"},{"key":"key20211117123226_b95-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1016\/S0140-6736(17)32247-X","article-title":"Effect of interleukin-1\u03b2 inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: Exploratory results from a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Ridker","year":"2017","journal-title":"Lancet"},{"key":"key20211117123226_b96-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1172\/JCI31405","article-title":"Immune surveillance of tumors","volume":"117","author":"Swann","year":"2007","journal-title":"J Clin Invest"},{"key":"key20211117123226_b97-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1002\/ejhf.942","article-title":"Immune mechanisms in heart failure","volume":"19","author":"Zhang","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"key20211117123226_b98-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/nri3800","article-title":"Role of innate and adaptive immune mechanisms in cardiac injury and repair","volume":"15","author":"Epelman","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"key20211117123226_b99-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/ejhf.1138","article-title":"The innate immune system in chronic cardiomyopathy: A European society of cardiology (ESC) scientific statement from the working group on myocardial function of the ESC","volume":"20","author":"Frantz","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"key20211117123226_b100-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1093\/eurheartj\/ehv007","article-title":"Expression of functional tissue factor by neutrophil extracellular traps in culprit artery of acute myocardial infarction","volume":"36","author":"Stakos","year":"2015","journal-title":"Eur Heart J"},{"key":"key20211117123226_b101-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/s0008-6363(01)00434-5","article-title":"The inflammatory response in myocardial infarction","volume":"53","author":"Frangogiannis","year":"2002","journal-title":"Cardiovasc Res"},{"issue":"79","key":"key20211117123226_b102-ETM-22-6-10898","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-00455-6","article-title":"A double-edged sword of immuno-microenvironment in cardiac homeostasis and injury repair","volume":"6","author":"Sun","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"key20211117123226_b103-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s11897-013-0155-7","article-title":"The emerging epidemic of heart failure with preserved ejection fraction","volume":"10","author":"Oktay","year":"2013","journal-title":"Curr Heart Fail Rep"},{"issue":"4273943","key":"key20211117123226_b104-ETM-22-6-10898","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/4273943","article-title":"The immune system in cancer pathogenesis: Potential therapeutic approaches","volume":"2016","author":"Pandya","year":"2016","journal-title":"J Immunol Res"},{"issue":"e1921618","key":"key20211117123226_b105-ETM-22-6-10898","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.21618","article-title":"Comparison of cardiovascular events among users of different classes of antihypertension medications: A systematic review and network meta-analysis","volume":"3","author":"Wei","year":"2020","journal-title":"JAMA Netw Open"},{"key":"key20211117123226_b106-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/S1470-2045(10)70106-6","article-title":"Angiotensin-receptor blockade and risk of cancer: Meta-analysis of randomised controlled trials","volume":"11","author":"Sipahi","year":"2010","journal-title":"Lancet Oncol"},{"key":"key20211117123226_b107-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S1470-2045(10)70260-6","article-title":"Antihypertensive drugs and risk of cancer: Network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials","volume":"12","author":"Bangalore","year":"2011","journal-title":"Lancet Oncol"},{"key":"key20211117123226_b108-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1097\/HJH.0b013e328344a7de","article-title":"Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals","volume":"29","year":"2011","journal-title":"J Hypertens"},{"key":"key20211117123226_b109-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1200\/JCO.2011.35.1908","article-title":"Angiotensin receptor blockade and risk of cancer in type 2 diabetes mellitus: A nationwide case-control study","volume":"29","author":"Chang","year":"2011","journal-title":"J Clin Oncol"},{"key":"key20211117123226_b110-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1093\/jnci\/djaa114","article-title":"Effect of aspirin on cancer incidence and mortality in older adults","volume":"113","author":"McNeil","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"key20211117123226_b111-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.bbadis.2012.02.003","article-title":"Possible roles of DLK1 in the Notch pathway during development and disease","volume":"1822","author":"Falix","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"key20211117123226_b112-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1093\/eurheartj\/ehy188","article-title":"Deletion of delta-like 1 homologue accelerates fibroblast-myofibroblast differentiation and induces myocardial fibrosis","volume":"40","author":"Rodriguez","year":"2019","journal-title":"Eur Heart J"},{"key":"key20211117123226_b113-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.bbrc.2010.02.048","article-title":"Delta-like 1 expression promotes goblet cell differentiation in Notch-inactivated human colonic epithelial cells","volume":"393","author":"Akiyama","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"key":"key20211117123226_b114-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s11010-018-3382-0","article-title":"Hsa-miR-370 inhibited P-selectin-induced cell adhesion in human colon adenocarcinoma cells","volume":"450","author":"Wei","year":"2019","journal-title":"Mol Cell Biochem"},{"key":"key20211117123226_b115-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"806","DOI":"10.4161\/cbt.28584","article-title":"MALAT1 promotes the proliferation and metastasis of gallbladder cancer cells by activating the ERK\/MAPK pathway","volume":"15","author":"Wu","year":"2014","journal-title":"Cancer Biol Ther"},{"issue":"e1506","key":"key20211117123226_b116-ETM-22-6-10898","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.466","article-title":"Pathogenic role of lncRNA-MALAT1 in endothelial cell dysfunction in diabetes mellitus","volume":"5","author":"Liu","year":"2014","journal-title":"Cell Death Dis"},{"key":"key20211117123226_b117-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1093\/cvr\/cvy202","article-title":"Immune system-mediated atherosclerosis caused by deficiency of long non-coding RNA MALAT1 in ApoE-\/-mice","volume":"115","author":"Gast","year":"2019","journal-title":"Cardiovasc Res"},{"key":"key20211117123226_b118-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1161\/CIRCULATIONAHA.117.029015","article-title":"Hematopoietic deficiency of the long noncoding RNA MALAT1 promotes atherosclerosis and plaque inflammation","volume":"139","author":"Cremer","year":"2019","journal-title":"Circulation"},{"issue":"104577","key":"key20211117123226_b119-ETM-22-6-10898","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.104577","article-title":"Role of cardioprotective agents on chemotherapy-induced heart failure: A systematic review and network meta-analysis of randomized controlled trials","volume":"151","author":"Li","year":"2020","journal-title":"Pharmacol Res"},{"key":"key20211117123226_b120-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1002\/ehf2.12493","article-title":"Heart failure from cancer therapy: Can we prevent it?","volume":"6","author":"Totzeck","year":"2019","journal-title":"ESC Heart Fail"},{"key":"key20211117123226_b121-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1124\/jpet.119.264580","article-title":"Investigation of structure-activity relationships of dexrazoxane analogs reveals topoisomerase II\u03b2 interaction as a prerequisite for effective protection against anthracycline cardiotoxicity","volume":"373","author":"Koll\u00e1rov\u00e1-Br\u00e1zdov\u00e1","year":"2020","journal-title":"J Pharmacol Exp Ther"},{"key":"key20211117123226_b122-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s00204-020-02951-8","article-title":"Dapagliflozin suppresses ER stress and protects doxorubicin-induced cardiotoxicity in breast cancer patients","volume":"95","author":"Chang","year":"2021","journal-title":"Arch Toxicol"},{"key":"key20211117123226_b123-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1152\/jappl.1997.83.1.160","article-title":"Age-related declines in maximal aerobic capacity in regularly exercising vs sedentary women: A meta-analysis","volume":"83","author":"Fitzgerald","year":"1997","journal-title":"J Appl Physiol (1985)"},{"key":"key20211117123226_b124-ETM-22-6-10898","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/00006199-198911000-00007","article-title":"Effects of aerobic interval training on cancer patients' functional capacity","volume":"38","author":"MacVicar","year":"1989","journal-title":"Nurs Res"},{"key":"key20211117123226_b125-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1158\/1940-6207.CAPR-12-0416","article-title":"Modulation of circulating angiogenic factors and tumor biology by aerobic training in breast cancer patients receiving neoadjuvant chemotherapy","volume":"6","author":"Jones","year":"2013","journal-title":"Cancer Prev Res (Phila)"},{"key":"key20211117123226_b126-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"4605","DOI":"10.1200\/JCO.2008.20.0634","article-title":"Randomized controlled trial of the effects of aerobic exercise on physical functioning and quality of life in lymphoma patients","volume":"27","author":"Courneya","year":"2009","journal-title":"J Clin Oncol"},{"key":"key20211117123226_b127-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1200\/JCO.2013.53.5724","article-title":"Safety and efficacy of aerobic training in patients with cancer who have heart failure: An analysis of the HF-ACTION randomized trial","volume":"32","author":"Jones","year":"2014","journal-title":"J Clin Oncol"},{"key":"key20211117123226_b128-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/s1728-869x(11)60009-9","article-title":"Exercise intervention for cancer survivors with heart failure: Two case reports","volume":"9","author":"Hughes","year":"2011","journal-title":"J Exerc Sci Fit"},{"issue":"2240","key":"key20211117123226_b129-ETM-22-6-10898","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12082240","article-title":"Aerobic exercise-induced changes in cardiorespiratory fitness in breast cancer patients receiving chemotherapy: A systematic review and meta-analysis","volume":"12","author":"Maginador","year":"2020","journal-title":"Cancers (Basel)"},{"key":"key20211117123226_b130-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.acvd.2020.03.020","article-title":"Role of humanin, a mitochondrial-derived peptide, in cardiovascular disorders","volume":"113","author":"Rochette","year":"2020","journal-title":"Arch Cardiovasc Dis"},{"issue":"683151","key":"key20211117123226_b131-ETM-22-6-10898","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.683151","article-title":"Protective mechanism of humanin against oxidative stress in aging-related cardiovascular diseases","volume":"12","author":"Cai","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"key20211117123226_b132-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.mito.2017.08.001","article-title":"Humanin directly protects cardiac mitochondria against dysfunction initiated by oxidative stress by decreasing complex I activity","volume":"38","author":"Thummasorn","year":"2018","journal-title":"Mitochondrion"},{"key":"key20211117123226_b133-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"H1127","DOI":"10.1152\/ajpheart.00685.2017","article-title":"Chronic treatment with the mitochondrial peptide humanin prevents age-related myocardial fibrosis in mice","volume":"315","author":"Qin","year":"2018","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"key20211117123226_b134-ETM-22-6-10898","doi-asserted-by":"publisher","first-page":"4511","DOI":"10.1210\/en.2015-1542","article-title":"The potent humanin analogue (HNG) protects germ cells and leucocytes while enhancing chemotherapy-induced suppression of cancer metastases in male mice","volume":"156","author":"Lue","year":"2015","journal-title":"Endocrinology"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"deposited":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T10:47:38Z","timestamp":1637146058000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/etm.2021.10898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,20]]},"references-count":134,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,10,20]]}},"URL":"https:\/\/doi.org\/10.3892\/etm.2021.10898","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"value":"1792-0981","type":"print"},{"value":"1792-1015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,20]]},"article-number":"1463"}}